Compare JMSB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMSB | ABEO |
|---|---|---|
| Founded | 2005 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0M | 281.0M |
| IPO Year | N/A | 1980 |
| Metric | JMSB | ABEO |
|---|---|---|
| Price | $19.85 | $5.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $22.50 | $18.20 |
| AVG Volume (30 Days) | 17.8K | ★ 1.1M |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 18.50 | N/A |
| EPS | ★ 1.40 | 1.29 |
| Revenue | ★ $59,274,000.00 | $400,000.00 |
| Revenue This Year | $19.50 | N/A |
| Revenue Next Year | $12.72 | $1,589.77 |
| P/E Ratio | $14.17 | ★ $4.08 |
| Revenue Growth | ★ 11.69 | N/A |
| 52 Week Low | $13.81 | $3.93 |
| 52 Week High | $21.58 | $7.54 |
| Indicator | JMSB | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 52.20 |
| Support Level | $19.35 | $4.98 |
| Resistance Level | $20.35 | $5.34 |
| Average True Range (ATR) | 0.41 | 0.24 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 41.67 | 37.18 |
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.